An early-stage Sage Therapeutics, but specializing in rapid-onset nasal spray medicines for anxiety and depression.

Similar to how GW Pharmaceuticals pioneered cannabinoid-based drugs for epilepsy, Vistagen is pioneering rapid-onset neuroactive nasal spray medicines for anxiety and depression.

• PH94B: A rapid-onset neuroactive nasal spray in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder, with potential for other anxiety disorders.
• PH10: A rapid-onset neuroactive nasal spray in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD).
• AV-101: An oral N-methyl-D-aspartate receptor antagonist in development as a potential treatment for levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation.

Vistagen Therapeutics (VTGN) is a clinical-stage biopharmaceutical company primarily focused on the research and development of medicines for Central Nervous System (CNS) disorders. Its drug candidates, such as PH94B, PH10, and AV-101, are currently in various phases of clinical development (Phase III, Phase 2B, and earlier development).

Given its stage of development, Vistagen Therapeutics does not currently have major customers in the traditional sense of selling commercialized products or services to other companies or individuals. Its business model at this stage involves advancing its drug pipeline through clinical trials and engaging in partnerships and licensing agreements related to its intellectual property, rather than generating revenue from direct product sales.

Cato Research Ltd.

Pherin Pharmaceuticals, Inc.

BlueRock Therapeutics, LP

Shawn K. Singh, President, Chief Executive Officer and Director

Mr. Singh has served as VistaGen's Chief Executive Officer since August 2009 and joined its Board of Directors in 2000. He has nearly 30 years of experience in the biotechnology, pharmaceutical, contract research, and venture capital industries. Prior to his role at VistaGen, Mr. Singh served as President of Artemis Neuroscience, which was acquired by VistaGen. He was also a Managing Principal of Cato BioVentures, a healthcare-focused venture capital firm, and Chief Business Officer and General Counsel of Cato Research Ltd. Earlier, he was Chief Business Officer of SciClone Pharmaceuticals, a public specialty pharmaceuticals company, and assisted with its IPO before co-founding Cato BioVentures. He began his career as a corporate finance attorney at Morrison & Foerster LLP. Mr. Singh also served as CEO of Hemodynamic Therapeutics, Chairman of Durham Pharmaceuticals, and Chairman of Echo Therapeutics. He is also a founding partner, CEO, and general counsel of Clear Sky Advisers.

Nick B. Tressler, Chief Financial Officer

Mr. Tressler joined VistaGen as Chief Financial Officer in December 2025. He brings over 20 years of financial leadership experience in the life sciences industry. Previously, he served as CFO of DYNEX Technologies from 2024 to 2025, and prior to that, he was CFO at American Gene Technologies International and Senseonics Holdings, Inc. Mr. Tressler has also held senior finance roles at several biopharmaceutical companies, including Sucampo Pharmaceuticals, which was acquired by Mallinckrodt in 2018, and MedImmune LLC, which was acquired by AstraZeneca PLC in 2007.

H. Ralph Snodgrass, President, Chief Scientific Officer and Founder

Dr. Snodgrass is a co-founder of VistaGen, establishing the company in 1998, and previously served as its CEO. He currently holds the positions of President and Chief Scientific Officer.

Elissa Cote, Chief Corporate Development Officer

Ms. Cote joined VistaGen as Chief Corporate Development Officer in 2025, bringing nearly 30 years of experience in business development and global partnerships. She previously held multiple senior-level roles at Mallinckrodt Pharmaceuticals, including Chief Strategy and Business Development Officer, where she led business development, licensing, and strategic divestitures. Ms. Cote also held leadership positions at Sucampo Pharmaceuticals and MedImmune Inc., the global biologics division of AstraZeneca PLC. Prior to joining VistaGen, she served as a fractional Chief Business Officer and strategic advisor to several biopharmaceutical clients and was a management consultant with Accenture plc.

Reid Adler, Chief Legal Officer

Mr. Adler joined VistaGen as Chief Legal Officer in May 2022 after serving as outside counsel for several years. His career spans over 35 years in life sciences innovation management. He has experience as a senior partner at international law firms Morrison & Foerster and Morgan Lewis, and served as general counsel to the J. Craig Venter Institute for genomics. Mr. Adler was also the founding director of the NIH Office of Technology Transfer and is the founder of InnovationMatters.

The key risks to Vistagen Therapeutics (VTGN) are primarily concentrated around its clinical-stage drug development and financial viability:

1. Clinical Trial Failures and Regulatory Approval: As a clinical-stage biopharmaceutical company, Vistagen's success is critically dependent on the successful completion of clinical trials and subsequent regulatory approval of its product candidates. The company's lead product candidate, fasedienol (PH94B), recently failed to meet its primary endpoint in the PALISADE-3 Phase 3 study for social anxiety disorder, leading to a significant drop in its stock price. This setback highlights the inherent risks in drug development, where there is no guarantee that any of Vistagen's candidates will successfully complete trials, receive regulatory approval, or achieve commercial success. The company is now focusing on the PALISADE-4 Phase 3 trial for fasedienol, with results expected in the first half of 2026.
2. Reliance on a Limited Product Pipeline: Vistagen's business is heavily concentrated on a small number of investigational product candidates, including PH94B, PH10, and AV-101, all of which are still in development and none are approved for commercialization. The failure of a single key candidate, such as fasedienol in PALISADE-3, has a substantial negative impact on the company's prospects and financial performance. This limited pipeline exposes the company to significant concentration risk.
3. Funding and Liquidity Challenges: The extensive and costly nature of clinical drug development means Vistagen requires substantial ongoing financing to support its research and development activities and execute its business plan. Following the disappointing PALISADE-3 results, Vistagen announced a workforce reduction of approximately 20% to implement cash preservation measures and extend its cash runway into 2027. The need to raise additional capital, potentially through equity offerings, carries the risk of significant dilution for existing shareholders.

The emergence of psychedelic-assisted therapies (e.g., psilocybin, MDMA) as potentially highly efficacious and rapidly acting treatments for major depressive disorder, social anxiety disorder, post-traumatic stress disorder, and other anxiety disorders poses a clear emerging threat. These therapies, many of which are in late-stage clinical development, represent a different treatment paradigm that could offer more profound and durable effects compared to Vistagen's drug candidates, potentially reducing the overall market for chronic or as-needed pharmacological interventions.

VistaGen Therapeutics (VTGN) has several product candidates targeting significant addressable markets for central nervous system disorders.

PH94B (Fasedienol)

• Indication: Social Anxiety Disorder (SAD)
• Market Size: The global social anxiety treatment market is estimated to reach $16,104.2 million (or $16.1 billion) by 2030. Another source suggests PH94B targets a potential $500 million to $1 billion market opportunity in Social Anxiety Disorder (SAD). Over 30 million adults in the U.S. are affected by SAD.
• Region: Global and U.S.

PH10 (Itruvone)

• Indication: Major Depressive Disorder (MDD)
• Market Size: The total addressable market for Major Depressive Disorder (MDD) treatment is expected to grow from USD 12,000 million (or $12 billion) in 2025 to USD 15,800 million (or $15.8 billion) by 2035 globally. Across the eight major markets (US, France, Germany, Italy, Spain, UK, Japan, and Canada), the MDD market is projected to reach $9.6 billion by 2029, growing from $4.7 billion in 2019. In the 7MM (United States, EU4, and the United Kingdom, and Japan), the MDD market size was approximately USD 7,165 million (or $7.165 billion) in 2023. The U.S. market alone for MDD was approximately USD 5,600 million (or $5.6 billion) in 2023.
• Region: Global, 8 Major Markets (US, France, Germany, Italy, Spain, UK, Japan, Canada), and 7MM (US, EU4, UK, Japan).

AV-101

• Indication: Levodopa-induced Dyskinesia (LID)
• Market Size: The Parkinson's Disease Levodopa-Induced Dyskinesia market was estimated to be approximately USD 1,500 million (or $1.5 billion) in 2023. The total Parkinson's Disease Levodopa-induced Dyskinesia treatment market size in the U.S. was approximately USD 900 million in 2023.
• Region: Global (estimated) and U.S.

• Indication: Major Depressive Disorder (MDD)
• Market Size: (Refer to PH10 for MDD market sizes, as AV-101 is also in development for MDD).
• Region: Global, 8 Major Markets (US, France, Germany, Italy, Spain, UK, Japan, Canada), and 7MM (US, EU4, UK, Japan).

• Indication: Neuropathic Pain
• Market Size: The global neuropathic pain market size was valued at $7.7 billion in 2022 and is projected to reach $13.3 billion by 2032. Another estimate places the global market at USD 8.59 billion in 2025, increasing to approximately USD 16.79 billion by 2034. North America held the largest market share of 50% in 2024. In 2024, the neuropathic pain market size was estimated at 7.8 USD Billion and is projected to reach 16.62 USD Billion by 2035.
• Region: Global and North America.

• Indication: Suicidal Ideation
• Market Size: While a specific market size for "suicidal ideation" as a standalone figure is not readily available, the "anti-suicide drugs market" is a relevant proxy. North America is expected to dominate the anti-suicide drugs market with a 39.20% share in 2026. The market for anti-suicide drugs is broad, considering the prevalence of mental health problems, especially mood and depressive disorders that raise the risk of suicide.
• Region: North America (primarily for anti-suicide drugs).

For Vistagen Therapeutics (NASDAQ: VTGN), key drivers of future revenue growth over the next 2-3 years are primarily linked to the advancement and potential commercialization of its clinical-stage pipeline candidates and the formation of strategic collaborations:

1. Successful Completion of Phase 3 Clinical Trials for PH94B (fasedienol) and Subsequent Regulatory Submission: Vistagen's lead product candidate, fasedienol, is in Phase 3 development for the acute treatment of social anxiety disorder (SAD). Positive top-line results from the ongoing PALISADE-4 Phase 3 trial are expected in the first half of 2026. Successful outcomes from this program, particularly when combined with previous positive results from PALISADE-2, are anticipated to support a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for fasedienol. Analysts have projected that fasedienol could achieve peak sales exceeding $1 billion, positioning it as a potential blockbuster therapy and a significant revenue driver upon approval.
2. Progression of PH10 (itruvone) into Later-Stage Clinical Development for Major Depressive Disorder (MDD): Vistagen is preparing for Phase 2B clinical development of itruvone as a stand-alone treatment for MDD. PH10 has received FDA Fast Track designation for MDD, which aims to expedite its development and review. Successful advancement through Phase 2B and into later-stage clinical trials would significantly enhance its market potential and represent a crucial step towards future revenue generation.
3. Strategic Partnerships and Advancement of AV-101: Vistagen plans to seek strategic partnering support to further advance the clinical development and commercialization of AV-101, an oral N-methyl-D-aspartate receptor antagonist. AV-101 has received FDA Fast Track designation for development as both an adjunctive treatment for MDD and a non-opioid treatment for neuropathic pain, highlighting its potential in significant unmet medical needs. The company is currently preparing for Phase 2A development. Securing new licensing agreements or collaborations for AV-101 could generate upfront payments, milestone payments, and future royalties, directly contributing to revenue growth.
4. Initiation of U.S. Phase 2 Clinical Development for PH80 (rificilone) in Women's Health: Vistagen is preparing to submit a U.S. Investigational New Drug Application (IND) for PH80 (rificilone) in the first half of 2026. This IND is intended to support further potential Phase 2 clinical development in the U.S. for the treatment of moderate to severe vasomotor symptoms due to menopause. Successful progression into U.S. clinical trials would diversify Vistagen's pipeline and open a new potential market opportunity, laying the groundwork for future revenue.

Share Issuance

• VistaGen Therapeutics completed a public offering in October 2023, raising approximately $93.5 million to primarily finance its operations.
• The company has an active Open Market Sale Agreement with Jefferies LLC, which allows for the sale of up to $100 million in common stock, with $96.9 million remaining available as of June 2025.
• Between March 31, 2024, and June 30, 2025, the number of common stock shares issued increased from approximately 27.03 million to 29.29 million, reflecting ongoing share issuances.

Inbound Investments

• VistaGen Therapeutics has entered into strategic collaborations that contribute to its capital, including a license and collaboration agreement with AffaMed Therapeutics for fasedienol in Asia and an exclusive negotiation agreement with Fuji Pharma for PH80 in Japan.

Capital Expenditures

• Capital expenditures for VistaGen Therapeutics have remained relatively low over the past few years, totaling $0.19 million for the fiscal year ended March 2025 and $0.24 million for the twelve months ended December 2025.
• Historically, capital expenditures were $0.06 million in March 2024 and $0.21 million in March 2023.
• These expenditures primarily relate to the purchase of laboratory and other equipment, supporting the company's research and development activities.